Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin.
Data are limited on the real-world utilization and costs of brentuximab vedotin (BV) among patients with relapsed/refractory Hodgkin lymphoma (rrHL) in the United States. A total of 219 BV patients identified from the Truven MarketScan® databases were followed up for a median of 2.9 years before and 1.0 year after initiation of BV. Of these patients, 109 (50.6%) received systemic therapy after BV (post-BV ST). Median duration of treatment was short for BV (2.1 months) and post-BV ST treatment (1.3 months); time to next treatment was 6.2 and 9.1 months, respectively. Average total US dollar 2014 costs/person for BV and post-BV ST line of therapy were $167,152 and $132,115, respectively; mean per-patient-per-month costs for BV and post-BV ST were $30,434 and $29,138, respectively. Findings underscore the unmet medical need and substantial economic burden in BV-treated patients with rrHL.
['Shao|Changxia|C|', 'Liu|Jinan|J|', 'Zhou|Wei|W|', 'Raut|Monika K|MK|', 'Monberg|Matthew|M|', 'Cao|Xiting|X|', 'Ricart|Alejandro D|AD|', 'Balakumaran|Arun|A|']
D000328:Adult D000368:Aged D000079963:Brentuximab Vedotin D003131:Combined Modality Therapy D003365:Costs and Cost Analysis D019008:Drug Resistance, Neoplasm D005260:Female D017048:Health Care Costs D006295:Health Resources D006689:Hodgkin Disease D006801:Humans D008297:Male D008875:Middle Aged D010342:Patient Acceptance of Health Care D010818:Practice Patterns, Physicians' D012008:Recurrence D012189:Retrospective Studies
treatment patterns health care resource utilization relapsed/refractory Hodgkin lymphoma Brentuximab vedotin cost analysis